ESPE Abstracts (2015) 84 FC4.1

ESPE2015 Free Communications Growth (6 abstracts)

Heterozygous Dominant Negative STAT5B Variants associated with Short Stature and GH Insensitivity

Evelien Pease-Gevers a , David Neumann b , Jurgen Klammt c , Shayne Andrew d , Julia Kowalczyk a , Lou Metherell a , Mehul Dattani e & Vivian Hwa d


aBarts Health NHS Trust/Queen Mary University London, London, UK; bUniversity Hospital Hradec Kralove, Hradec Kralove, Czech Republic; cUniversity of Leipzig, Leipzig, Germany; dCincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; eGreat Ormond Street Hospital, London, UK


Background: Homozygous mutations in STAT5B result in GH insensitivity and immune dysfunction. Heterozygous dominant negative mutations have not been described.

Aims and objectives: To characterize genomic STAT5B DNA in two families exhibiting short stature.

Methods: Sanger sequencing of STAT5B from genomic DNA. Mutant STAT5B constructs were expressed in HEK293 cells.

Results: Family 1: The index case grew at −2.9S.D. from the age of 2 years. Investigations revealed IGF1 <25 ng/ml, IGFBP3 1.29 ng/ml (NR0.8–3.9), prolactin 265–65 3 mU/l (NR59-271), GH-peak (glucagon test) 17.3 μg/l, and normal GH-peaks on overnight sampling. A standard and extended 3-step IGF1-generation test (2 weeks GH sc at 0.7, 1.4 and 2.4; mg/m2 per day) showed a poor response. His brother had short stature (−2.9S.D.), mild speech delay, eczema, undetectable IGF1, a GH peak of 13.9 μg/l and poor response in the IGF1-generation test. Both brothers had elevated IgE concentrations. Family histories were positive for short stature, eczema and transient hyperprolactinaemia. A heterozygous missense variant c.1433C>T (p.Ala478Val) was identified within the conserved STAT5B DNA-binding domain, and segregated with the phenotype. Family 2: Male monozygotic twins presented at age 14 years with short stature (−5.3SDS), eczema and a history of mild respiratory infections. Investigations revealed a provoked GH peak of 16.2 μg/l, low IGF1 (56 μg/l) and elevated IgE concentrations. rhIGF1 therapy led to modest catch-up growth. A de novo heterozygous variant (c.530A>C; p.Gln177Pro) was identified. Neither of the STAT5B variants are listed in control databases. Functional evaluation of the FLAG-STAT5B mutants indicated normal protein expression and phosphorylation but severely compromised nuclear translocation and transcriptional function compared to WT. Both variants inhibited translocation and transcription activity of WT FLAG-STAT5B, suggesting a dominant-negative mode of action.

Conclusion: This is the first description of dominant-negative STAT5B mutations in subjects with short stature and mild GH insensitivity. Eczema may also be related to impaired STAT5B function.

Volume 84

54th Annual ESPE (ESPE 2015)

Barcelona, Spain
01 Oct 2015 - 03 Oct 2015

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.